Racura Enters Underwriting Agreement for Options
Open PDF
| Stock | Race Oncology Ltd (RAC.ASX) |
|---|---|
| Release Time | 28 May 2026, 4:43 p.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Racura Enters Underwriting Agreement for Options
Key Points
- $1.25 Piggyback Options exercised yielding $22.879M
- Agreement with existing shareholder fully underwrites remaining options
- Total raised from Piggyback Options to be $25.2M upon full conversion
Full Summary
Racura Oncology Ltd. announced the execution of an underwriting agreement with Dr. AJ Robinson to cover any remaining unexercised $1.25 Piggyback options. This agreement ensures that up to 1,838,524 options will be exercised, raising a maximum of approximately $2.298M. The underwriting is provided by an existing shareholder, with no underwriting fee, commission, or other consideration. The funds will support Racura's clinical programs in AML, lung cancer, and anthracycline cardioprotection, as well as general working capital.
Guidance
Total raised from Piggyback Options to be $25.2M upon full conversion
Outlook
The underwriting agreement aims to ensure continued funding for Racura's clinical development programs, supporting their mission to silence cancer.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In